RIPK3 Inhibition Mitigates Denervated Muscle Atrophy via NOX4‐Mediated Mitochondrial Restoration and Inflammation Suppression
Journal of Cachexia, Sarcopenia and Muscle · 2026
DOI: 10.1002/jcsm.70311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cachexia, Sarcopenia and Muscle, 2026. Verfasst von Yuntian Shen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Medical School of Nantong University, Co-Innovation Center of Neuroregenera…. Hauptthemen laut MEDLINE: Muscular Atrophy, NADPH Oxidase 4, Inflammation, Receptor-Interacting Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Nantong Science and Technology Bureau, Natural Science Foundation of Jiangsu Province.
Abstract (Originalsprache)
Background
Peripheral nerve injury‐induced muscle atrophy shares core pathophysiological features with systemic wasting disorders including cachexia and sarcopenia, yet early molecular triggers remain undefined. This study investigates the pathogenic role of receptor‐interacting protein kinase 3 (RIPK3) in denervation atrophy.
Methods
Sciatic denervation was induced in rats for initial time‐course transcriptomics and in mice for genetic and pharmacological studies. Assessments in wild‐type and RIPK3‐knockout mice included transcriptomics (RNA‐seq, qPCR), muscle morphology (wet weight ratio, cross‐sectional area), histological inflammation (H&E, CD68 immunofluorescence), mitochondrial function (complex I/V activity, ultrastructure and biogenesis/fission regulators), STRING analysis to identify downstream effectors, validated key effectors NOX2 and NOX4 (qPCR/Western blotting) and associated redox status (DHE staining), and analysis of myofibrillar protein content and proteolytic markers (Western blotting). Confirmatory studies included RIPK3 overexpression in C2C12 myotubes and its pharmacological inhibition (GSK872) in mice.
Results
RIPK3 emerged from transcriptomic analysis as an early upregulated mediator in denervated muscle, with protein levels increasing approximately threefold at 36 h post‐injury. Genetic ablation of RIPK3 attenuated muscle atrophy, as shown by improved gastrocnemius wet weight ratio ( p = 0.0110). This protective effect was directly evidenced by a 40.7% increase in cross‐sectional area ( p = 0.04). The morphological preservation was accompanied by markedly suppressed expression of key atrophy markers, including MAFbx, MuRF1 and FoxO3a (all p < 0.01), and preserved MHC levels ( p = 0.0278). Mechanistically, RIPK3 knockout reduced inflammation, enhanced oxidative phosphorylation (GSEA FDR < 0.001) and partially restored mitochondrial function, evidenced by significantly increased complex I ( p = 0.0438) and complex V ( p < 0.001) activity, preserved ultrastructure, upregulated PGC‐1α and NRF2 (both p < 0.05) and downregulated mitochondrial fission proteins (p‐DRP1, MFF, FIS1; all p < 0.01). STRING analysis predicted NOX4 as a key downstream effector, validated by reduced NOX4 protein (−46.6%, p = 0.0366) and a consequent 52.2% decrease in ROS accumulation ( p < 0.001). Consistently, RIPK3 overexpression in C2C12 myotubes elevated NOX4 ( p = 0.0046) and atrophy markers, whereas pharmacological inhibition of RIPK3 in mice replicated the protective phenotype, increasing muscle wet weight ratio ( p = 0.0277) and suppressing NOX4 ( p = 0.0398) and proteolytic markers.
Conclusions
Denervation activates RIPK3 as a master regulator that drives muscle atrophy via NOX4/ROS‐induced mitochondrial dysfunction, sustained inflammation and ubiquitin–proteasome activation. Targeting RIPK3 preserves muscle mass and may offer a novel therapeutic strategy for neurogenic muscle atrophy, with possible implications for related wasting disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Medical School of Nantong University, Co-Innovation Center of Neuroregeneration, Nantong University, Nantong, Jiangsu, China.
- Department of Orthopedics, Changshu Hospital Affiliated to Soochow University, First People's Hospital of Changshu City, Changshu, Jiangsu, China.
ORCID-Profile: Hualin Sun
Förderung
- National Natural Science Foundation of China
- Nantong Science and Technology Bureau
- Natural Science Foundation of Jiangsu Province
- Natural Science Research Projects in Universities of Jiangsu Province
- Suzhou Science and Technology Development Program
Zitieren
APA
Shen, Y., Zhang, C., Zhao, Z., Yi, J., Yao, X., Chen, B., & Sun, H. (2026). RIPK3 Inhibition Mitigates Denervated Muscle Atrophy via NOX4‐Mediated Mitochondrial Restoration and Inflammation Suppression. Journal of Cachexia, Sarcopenia and Muscle. https://doi.org/10.1002/jcsm.70311
Vancouver
Shen Y, Zhang C, Zhao Z, Yi J, Yao X, Chen B, et al. RIPK3 Inhibition Mitigates Denervated Muscle Atrophy via NOX4‐Mediated Mitochondrial Restoration and Inflammation Suppression. Journal of Cachexia, Sarcopenia and Muscle. 2026. doi:10.1002/jcsm.70311
BibTeX
@article{Shen2026,
author = {Shen, Yuntian and Zhang, Chen and Zhao, Zihao and Yi, Jia and Yao, Xinlei and Chen, Bingqian and Sun, Hualin},
title = {RIPK3 Inhibition Mitigates Denervated Muscle Atrophy via NOX4‐Mediated Mitochondrial Restoration and Inflammation Suppression},
journal = {Journal of Cachexia, Sarcopenia and Muscle},
year = {2026},
doi = {10.1002/jcsm.70311}
}
EUVIMED